CU20220013A7 - Proceso industrial para la preparación de estetrol de alta pureza - Google Patents
Proceso industrial para la preparación de estetrol de alta purezaInfo
- Publication number
- CU20220013A7 CU20220013A7 CU2022000013A CU20220013A CU20220013A7 CU 20220013 A7 CU20220013 A7 CU 20220013A7 CU 2022000013 A CU2022000013 A CU 2022000013A CU 20220013 A CU20220013 A CU 20220013A CU 20220013 A7 CU20220013 A7 CU 20220013A7
- Authority
- CU
- Cuba
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- formula
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title abstract 2
- 229950009589 estetrol Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>La invención se refiere a la preparación de estetrol de fórmula (I), derivados del mismo, protegidos en las posiciones 3,15α, 16α, 17β de fórmula general (III), y derivados 3-hidroxi del mismo protegidos en las posiciones 15α, 16α, 17β de fórmula general (IV), y a los productos intermedios de fórmulas generales (III) y (IV) aplicados en el proceso, que permite su producción en alta pureza y puede llevarse a cabo a través de intermediarios con propiedades ventajosas (por ejemplo, cristalización, purificación aislabilidad, rendimiento).</p> <p>ESPACIO PARA FORMULA</p> <p> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| PCT/IB2020/058148 WO2021044302A1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20220013A7 true CU20220013A7 (es) | 2022-10-11 |
| CU24692B1 CU24692B1 (es) | 2024-01-10 |
Family
ID=89992977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000013A CU24692B1 (es) | 2019-09-03 | 2020-09-02 | Proceso industrial para la preparación de estetrol de alta pureza |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11633406B2 (es) |
| EP (1) | EP3877395B1 (es) |
| JP (1) | JP7265087B2 (es) |
| KR (1) | KR20220071206A (es) |
| CN (1) | CN114302889B (es) |
| AU (1) | AU2020343497B2 (es) |
| CA (1) | CA3147815C (es) |
| CL (1) | CL2022000492A1 (es) |
| CO (1) | CO2022003769A2 (es) |
| CU (1) | CU24692B1 (es) |
| DK (1) | DK3877395T3 (es) |
| EC (1) | ECSP22022403A (es) |
| ES (1) | ES2855923T3 (es) |
| FI (1) | FI3877395T3 (es) |
| HR (1) | HRP20230230T1 (es) |
| HU (2) | HU231240B1 (es) |
| IL (1) | IL290973B2 (es) |
| JO (1) | JOP20220041A1 (es) |
| LT (1) | LT3877395T (es) |
| MA (1) | MA54200B1 (es) |
| MD (1) | MD3877395T2 (es) |
| MX (1) | MX2022002603A (es) |
| PE (1) | PE20221418A1 (es) |
| PL (1) | PL3877395T3 (es) |
| PT (1) | PT3877395T (es) |
| RS (1) | RS63966B1 (es) |
| SI (1) | SI3877395T1 (es) |
| WO (1) | WO2021044302A1 (es) |
| ZA (1) | ZA202203557B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220348607A1 (en) * | 2019-09-27 | 2022-11-03 | Industriale Chimica S.R.L. | Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene- 3,15,16,17-tetrol (estetrol) and intermediates of said process |
| WO2023051937A1 (en) * | 2021-10-01 | 2023-04-06 | Industriale Chimica S.R.L. | Process for preparing (15alpha,16alpha,17 eta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| PT1390040E (pt) | 2001-05-18 | 2007-04-30 | Pantarhei Bioscience Bv | Composição farmacêutica para ser utilizado na terapia hormonal de substituição. |
| ATE449606T1 (de) | 2001-05-23 | 2009-12-15 | Pantarhei Bioscience Bv | Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption |
| US7732430B2 (en) | 2001-05-23 | 2010-06-08 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
| WO2003041718A1 (en) | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| WO2003103684A1 (en) | 2002-06-11 | 2003-12-18 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| EP1511498B1 (en) | 2002-06-11 | 2012-11-21 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| EP1526856B1 (en) | 2002-07-12 | 2008-01-02 | Pantarhei Bioscience B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| CA2503549C (en) | 2002-10-23 | 2012-07-10 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| DE60332754D1 (de) * | 2002-11-08 | 2010-07-08 | Pantarhei Bioscience Bv | Synthese von oestetrol aus von oestron abgeleiteten steroiden |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| EP2114412B1 (en) | 2007-01-08 | 2010-07-14 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| EP2383279A1 (en) * | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| HUE033590T2 (hu) | 2011-08-11 | 2017-12-28 | Estetra Sprl | Esztetrol alkalmazása sürgõsségi fogamzásgátlóként |
| JP6196625B2 (ja) | 2011-10-07 | 2017-09-13 | エステトラ エス．ペ．エール．エル． | エステトロールを製造するための方法 |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
| US9988417B2 (en) * | 2013-09-18 | 2018-06-05 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| MX369035B (es) | 2013-12-12 | 2019-10-25 | Donesta Bioscience B V | Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol. |
| SI3310345T1 (sl) | 2015-06-18 | 2021-05-31 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
| RS61777B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetrol |
| ME03728B (me) | 2015-06-18 | 2021-01-20 | Estetra Sprl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
| CA3071660A1 (en) | 2017-08-01 | 2019-02-07 | Fund Sa | Adjuvant therapy for use in prostate cancer treatment |
| SG11202007163WA (en) | 2018-02-07 | 2020-08-28 | Estetra Sprl | Contraceptive composition with reduced cardiovascular effects |
| US20220348607A1 (en) | 2019-09-27 | 2022-11-03 | Industriale Chimica S.R.L. | Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene- 3,15,16,17-tetrol (estetrol) and intermediates of said process |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 CA CA3147815A patent/CA3147815C/en active Active
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/en active Active
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 KR KR1020227010919A patent/KR20220071206A/ko unknown
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/en active Application Filing
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| CU20220013A7 (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
| MY172391A (en) | Processes for preparing dihydropyrimidine derivatives and intermediates thereof | |
| CL2012000581A1 (es) | Proceso para la preparacion de 1-cloro-4-(ß-d-glucopiranos-1-il)-2-[4-tetrahidrofuran-3-iloxi-bencil]-benceno con separacion de fases mediada por la adicion de acidos. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
| BR112018076243A2 (pt) | método para produção de derivado de difenil metano | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| GT201300253A (es) | Preparacion de gadobutrol de alta pureza | |
| MX2018005733A (es) | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). | |
| UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
| UY31278A1 (es) | Nuevos derivados de n, n??-2,4-dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk | |
| BRPI0814126A2 (pt) | Processo para a preparação de drospirenona | |
| AR086987A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| UY30851A1 (es) | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos | |
| CL2022000904A1 (es) | Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). | |
| NI201200177A (es) | Intermedios de agomelatina y método de preparación de estos | |
| BR112017017066A2 (pt) | método de preparação para praziquantel e compostos intermediários do mesmo | |
| BR112019000291A2 (pt) | processos inovadores para a preparação de estimuladores de guanilato ciclase solúvel | |
| BR112019002432A2 (pt) | cristalização de glicosídeos de esteviol | |
| BR112014027994A2 (pt) | métodos de cristalização para purificação de anticorpos monoclonais | |
| AR111465A1 (es) | Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes | |
| MY176613A (en) | Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue | |
| CL2019000074A1 (es) | Método de producción de cristal de compuesto de uracilo. |